Nilvebrant L, Gillberg P G, Sparf B
Medical Department Urology, Pharmacia & Upjohn AB, Uppsala, Sweden.
Pharmacol Toxicol. 1997 Oct;81(4):169-72. doi: 10.1111/j.1600-0773.1997.tb02064.x.
PNU-200577 (labcode DD 01 [(R)-N, N-diisopropyl-3-(2-hydroxy-5-hydroxymethylphenyl)-3-phenylpropanamine ) is a major pharmacologically active metabolite of tolterodine, a new muscarinic receptor antagonist intended for the treatment of an overactive bladder. In vitro, PNU-200577 produced a competitive and concentration-dependent inhibition of carbachol-induced contraction of guinea-pig isolated urinary bladder strips (KB = 0.84 nM; pA2 = 9.14). In vivo, PNU-200577 was significantly more potent at inhibiting acetylcholine-induced urinary bladder contraction than electrically induced salivation in the anaesthetised cat (ID50 15 and 40 nmol.kg-1, respectively; P < 0.01). In radioligand binding studies carried out in homogenates of guinea-pig tissues and Chinese hamster ovary cell lines expressing human muscarinic m1-m5 receptors, PNU-200577 was not selective for any muscarinic receptor subtype. Thus, PNU-200577 is similar to tolterodine in terms of antimuscarinic potency, functional selectivity for the urinary bladder in vivo and absence of selectivity for muscarinic receptor subtypes in vitro. The results of this study clearly indicate that PNU-200577 contributes to the therapeutic action of tolterodine, in view of its high antimuscarinic potency, similar serum concentration and lower degree of protein binding.
PNU - 200577(实验室代码DD 01[(R)-N,N -二异丙基-3-(2 -羟基-5 -羟甲基苯基)-3 -苯基丙胺])是托特罗定的一种主要药理活性代谢物,托特罗定是一种新型毒蕈碱受体拮抗剂,用于治疗膀胱过度活动症。在体外,PNU - 200577对卡巴胆碱诱导的豚鼠离体膀胱条收缩产生竞争性和浓度依赖性抑制作用(平衡解离常数KB = 0.84 nM;拮抗常数pA2 = 9.14)。在体内,PNU - 200577在抑制乙酰胆碱诱导的膀胱收缩方面比在麻醉猫中电诱导的唾液分泌显著更有效(半数抑制剂量ID50分别为15和40 nmol·kg-1;P < 0.01)。在豚鼠组织匀浆和表达人毒蕈碱m1 - m5受体的中国仓鼠卵巢细胞系中进行的放射性配体结合研究中,PNU - 200577对任何毒蕈碱受体亚型均无选择性。因此,PNU - 200577在抗毒蕈碱效力、体内对膀胱的功能选择性以及体外对毒蕈碱受体亚型无选择性方面与托特罗定相似。鉴于其高抗毒蕈碱效力、相似的血清浓度和较低的蛋白结合程度,本研究结果清楚地表明PNU - 200577有助于托特罗定的治疗作用。